A Headlands Research Site

Facebook
Twitter
LinkedIn

Donate Now

About Us
Patients
Physicians
Sponsors
Clinical Trials
Media
Contact

Media

Cassava sciences – Sumifilam

Cassava sciences - Sumifilam

This video describes the medication under investigation in the PTI-125-004 Alzheimer’s disease clinical trial

Search for:

Recent Posts

Hope and anxiety surround new Alzheimer’s drug lecanemab
Experimental drug appears to slow progression of Alzheimer’s disease in clinical trial but raises safety concerns
A New Drug Could Slow Alzheimer’s Disease, Data Show
A potential breakthrough in Alzheimer’s research needs Canadians’ help to move forward
An experimental Alzheimer’s drug could be approved next year. But it comes with risks
Ontario not ready for new Alzheimer’s treatment
Assessing Lecanemab’s Effect in Early Alzheimer Disease: Sharon Cohen, MD, FRCPC
Dr. Sharon Cohen on Medcan’s podcast series called Eat, Move, Think!
Dr. Sharon Cohen on CanadaTalks with Matt Gurney
CTV News Channel with Dr. Sharon Cohen on FDA approval of Aducanumab

Media Requests

If your organization would like to make a request, please use one of the following two options:

Call: (416) 386-9761 Ext. 364
Email: media@memorydisorders.ca

Latest Tweets

The journey to understanding Alzheimer's began in the late 1890s with Auguste Deter, a woman whose memory loss intrigued Dr. Alois ...Alzheimer. His observations of her symptoms led to the identification of the brain changes associated with the disease.

The history behind Alzheimer's disease

While Alzheimer's has always been with us, attempts to understand and identify the disease and its impact didn't c...

alzheimer.ca

Reply on Twitter 1841820381033722322 Retweet on Twitter 1841820381033722322 0 Like on Twitter 1841820381033722322 0 Twitter 1841820381033722322

As Ontario navigates the future of public access to new medicines, disease-modifying Alzheimer's treatments must be a priority. “This is ...an all-too-common disease affecting many Canadians,” says Dr. Sharon Cohen.

How Ontario Could Lead Access to Alzheimer’s Medicines

As Ontario works to better prioritize public access to new medicines, disease-modifying Alzheimer’s medicines must be ...

www.healthinsight.ca

Reply on Twitter 1841104115729895774 Retweet on Twitter 1841104115729895774 1 Like on Twitter 1841104115729895774 2 Twitter 1841104115729895774

Load More...

A Headlands Research Company

Facebook
Twitter
LinkedIn

1 Valleybrook Dr, North York, ON M3B 2S7, Canada

About Us
Patients
Physicians
Sponsors
Studies
In the Media
Contact Us

Monday - Friday: 8am - 4pm

© 2024 Toronto Memory Program. All rights reserved.

View Privacy Policy